

S1 Table. Initial treatment of patients with stage III lung cancer

Initial treatment	No. (%)	Reason(s) not to perform CCRT
CCRT	18 (56.3) ^{a)}	
ICI	2 (6.3)	Poor lung function with high PD-L1 expression
Small molecule targeted agent	1 (3.1)	Poor lung function with <i>EGFR</i> mutation
Cytotoxic agent	11 (34.4)	Extensive lung field for RT (4), poor lung function (5), underlying IPF (1), cancer progression during neoadjuvant chemotherapy (1)

CCRT, concurrent chemoradiotherapy; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; IPF, idiopathic pulmonary fibrosis; PD-L1, programmed death ligand-1; RT, radiotherapy. ^{a)}One patient stopped CCRT after 5,400 cGy due to brain progression.